Breast cancer and the pill--a further report from the Royal College of General Practitioners' oral contraception study. by Kay, C. R. & Hannaford, P. C.
B8 The Macmillan Press Ltd., 1988
Breast cancer and the pill - A further report from the Royal College
of General Practitioners' oral contraception study
C.R. Kay & P.C. Hannaford
RCGP Manchester Research Unit, 8 Barlow Moor Road, Manchester M20 OTR, UK.
Summary An analysis of the occurrence of breast cancer in this long-term prospective cohort study shows a
significant relative risk (RR) in women who have ever used oral contraceptives (OC) of 3.33 in women age 30
to 34 years at diagnosis and an RR of 5.88 (P=0.00l1) in women who were parity 1 at the time of diagnosis.
In women below the age of 35 years the RR of 2.38 was not significant. There was no increased risk in
women over the age of 35 years. A significant trend relating to duration of use was demonstrable in women
who were parity 1 in the analysis of both current and ever-users. An analysis by time since stopping OC use
revealed a significant trend in all ever-users, but the trends were much steeper in women of parity 1 or aged
30 to 34 years at diagnosis. There was no evidence that the increased rates in OC users were related to the
oestrogen or progestogen dose. The 5 year survival rate in users diagnosed under the age of 35 years was
significantly poorer than in comparable non-users.
It is possible that the increased rates in younger OC users might be due to an accelerated presentation of
breast cancer in those women who would otherwise have been diagnosed at a later time. The non-significant
excess risk in users under 35 years of age was approximately 1 in 7,000 users per year.
The unresolved discrepancies between the results of the published studies make it impossible at the present
time to decide whether or not OC use is associated with an increased risk of breast cancer.
The association of oral contraceptive use with breast cancer
remains unresolved. While some workers have found no
increased risk, others have found an increased risk in certain
subgroups of young women, for example those who have
used oral contraceptives (OCs) before the age of 25 years, or
before their first full-term pregnancy. The last report from
the Royal College of General Practitioners' (RCGP) cohort
study relating to breast cancer was published in 1981 (Royal
College of General Practitioners, 1981). At that time there
was no overall risk of breast cancer evident in pill users,
although women aged 30 to 34 years at diagnosis had a
relative risk (RR) of 3.33. The present report is based upon
data available in March 1985. The number of breast cancer
cases has increased from 133 presented in the 1981 report to
239, and the total cohort experience from 306,286 to 406,836
women-years.
Subjects and methods
The Study organisation, the potential biases, and the prin-
ciples underlying the interpretation of the data have been
detailed elsewhere (Royal College of General Practitioners,
1974). Briefly, during a 14 month period which started in
May 1968, 23,000 women using oral contraceptives and a
similar number of controls who had never used oral contra-
ceptives were recruited by 1,400 general practitioners
throughout the United Kingdom. Due to a loss to follow-up
at the time of these analyses, 18,000 of the original 47,000
subjects remained under observation. All women were
married, or living as married, and users and their controls
were matched for age. At six-monthly intervals from her
respective date of recruitment, the general practitioner sup-
plies details about the subject's oral contraceptive use, all
newly presenting episodes of illness and other relevant data.
For each calendar month in which a subject uses an oral
contraceptive, one month is added to the period of exposure
of current users. If the woman stops using the pill her
subsequent periods of observation are included in the former
user group, unless she restarts use, in which case she again
contributes to the current users' periods of observation.
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Controls are those women who have never used the pill. If a
woman is recruited as a control but starts to use the pill, her
subsequent experience is categorised in the same manner as
other users. In most of the analyses it is more appropriate to
combine the experience of current users with that of former
users, and to study all those who have ever used oral
contraceptives.
Thus, according to their characteristics at the time, women
contribute months of observation and associated events to
the relevant strata of all variables. This principle is main-
tained throughout the analyses. For example, suppose a
woman has experienced a total of 37 months of oral
contraceptive use, followed by 100 months of observation as
a former user. In the analysis by duration of current use she
will contribute 24 months to the stratum '<2 years' and 13
months to the stratum '2+3 years'. When the analysis relates
to ever-users her 100 months of observation as a former user
is added to the '2+3 years' stratum.
The analyses are based on the first report of the diagnosis
of breast cancer in any woman after recruitment to the
study. Event rates are calculated for each group using the
cumulative relevant women-months of observation as a
denominator, and are expressed as rates per thousand
women-years. Unless stated otherwise, the rates are indir-
ectly standardised for age and parity at the time of diagnosis
and daily cigarette consumption and social class at recruit-
ment. The total study population is normally used as the
reference for the indirect standardisation. Statistical tests for
differences between the groups are calculated using the
method described by Peto et al. (1977). The 95% confidence
intervals are calculated using Miettinen's (1976) test-based
method or, when more convenient, derived from the assump-
tion that the standard deviation of the log relative risk is
equal to the sum of the reciprocals of the observed number
of cases in the two groups being compared. Tests for linear
trends are based on Mantel's (1963) method modified to
accommodate standardised data.
Pregnancy modifies the occurrence and reporting of many
diseases, and the pregnancy rate was lower in those who had
ever-used oral contraceptives than in the controls. All events
reported during pregnancy are excluded, together with the
associated women-months of observation. This is consistent
with the presentation of our other morbidity data. When,
however, pregnancy is included in the breast cancer analysis,
no important change occurs in the results.
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Whenever it is possible to obtain the original specimens,
the histology of the reported breast cancers is assessed by an
independent histopathologist who does not know the contra-
ceptive status of the patient. The system described by Scarff
and Torloni (1968) is used to classify and grade the tumours.
When the diagnosis of breast cancer is notified to the unit
the general practitioner is asked to detail the manner in
which the breast lesion has been discovered, and the age at
which the patient gave birth to her first child. Age at first
birth is an important determinant of the subsequent risk of
developing breast cancer (Macmahon et al., 1970). Unfortu-
nately the need for this information for the whole study
population was not recognised at recruitment, and so it is
not known whether important differences in this variable
exist between the contraceptive groups. Parity, however, is
correlated with age at first birth (Macmahon et al., 1970),
and so the effects of any differences in the age at first birth
between the groups should be reduced by standardisation for
par-ity.
Survival times in women diagnosed as having breast
cancer were analysed by life table analysis (Peto et al., 1977).
Results
The standardised breast cancer rates for current users of oral
contraceptives, former users and controls are given in Table
I; neither -of the risk ratios (RR) between current users and
controls (RR 1.25) or former users and controls (RR 1.21)
were significant. Table II shows the risk ratio between ever-
users and controls, which overall was also not significant
(RR 1.2). However, users aged 30 to 34 years at diagnosis
had a significantly increased risk ratio of breast cancer of
3.33. This is identical to our previous finding, although there
are now five additional cases in ever-users and none in the
controls. As in our 1981 publication, there was no evidence
of an increased risk in users aged 35 to 44. The modestly
increased relative risks in older women are not significant
and have wide confidence intervals (CI). The relative risk in
all women under 35 years of age was 2.38, and this was not
statistically significant.
Table III shows an analysis by parity at the time of
diagnosis. There was no material increase in the risk ratio in
any parity group, except parity 1 where the relative risk was
5.88 (P=0.0011, 95% CI 2.02-17.1).
The age of starting OCs was recorded. Those women who
began OCs before the age of 25 years did not differ
materially in their breast cancer risk from those who began
at a later age.
The age at the first term birth is known only for the
breast cancer cases. There was no material difference
between users and controls (mean age 24.6 and 25.6 years,
respectively).
Analyses were performed to see if the positive findings
could be explained by differences between the habits and
experience of women born at different times. The women
were divided into those born before 1929, in 1930 to 1934,
1935 to 1939, and after 1940, then analysed in five-year age
bands. No birth cohort effect was apparent in any of the
analyses.
Table IV shows the breast cancer rates in ever-users by
duration of use. There is no evidence of a trend with
increasing length of use when all subjects are included in the
analysis. However, a highly significant trend emerges when
the analysis is confined to women of parity I at the time of
their diagnosis. There is also a suggestion of a trend in
women aged 30 to 34 years at diagnosis, but this falls short
of the conventional level of statistical significance.
Amongst current users there was no evidence of a trend in
relation to duration of use when all subjects are included,
nor in women aged 30-34 years. In women of parity 1,
however, not only is there a highly significant trend of
increasing risk with increasing duration of use (Table V) but
the relative risks of 5.67 and 7.06 are both significant at the
5% level in the strata 2+3 years and 4+5 years, respectively.
The analysis by duration of use in current users investi-
gates the time relationships of reported events between
starting and stopping OCs. An analysis of recency provides
complementary data about the reporting of events in former
users since they stopped OCs. The results are shown in Table
VI. For all former users the rates vary from stratum to
stratum, but reach a peak relative risk of 1.85 ten or more
Table I Standardised breast cancer rates per 1,000 women-years by oral contraceptive use. Standardised by
the indirect method for age and parity at diagnosis, social class and cigarette consumption at recruitment
Standardised Period of observation Risk ratio vs. controls
rate (TWY) (women-years) (95% confidence interval)
Current users (n=44) 0.66 104,505 1.25 (0.84-1.86)
Former users (n=99) 0.63 134,079 1.21 (0.89-1.65)
Controls (n=96) 0.52 168,252 1.00
Table II Breast cancer by age at diagnosis. Standardised by the indirect method for parity at diagnosis and social class and
smoking habit at recruitment. Total and subtotal were also standardised for age at diagnosis
Ever-users
Standardised
No. rate (TWY)
0
S
22
0
0.12
0.41
27 0.24
22
31
43
17
3
0
0.42
0.83
2.06
1.86
1.36
0
143 0.64
Controls
Standardised Risk ratio
No. rate (TWY) Ever-users:Controls
4
0.17
0.05
0.12
6 0.10
17
28
27
12
5
l
0.45
0.84
1.15
1.06
1.17
0.95
2.53
3.33a
2.38
0.94
0.99
1.78
1.75
1.16
95% confidence interval
(0.12-52.48)
(1.26-8.77)
(0.98-5.76)
(0.28-3.16)
(0.94-1.05)
(0.75-4.21)
(0.15-20.33)
(0.06-21.27)
'P<0.05; TWY=thousand woman-years.
Age at
diagnosis
(years)
<24
25-29
30-34
<35
35-39
40-44
45-49
50-54
55-59
60-64
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Table III Breast cancer rates by parity. Standardised by the indirect method for age at diagnosis and social class and smoking
habit at recruitment
Ever-users Controls
Parit at Standardised Standardised Risk ratio
diagnosis No. rate (TWY) No. rate (TWY) Ever-users: Controls 95% confidlence interval
0 3 0.42 1 1 0.37 1.14 (0.72-1.8)
1 20 0.93 7 0.16 5.88a (2.02-17.1)
2+ 3 99 0.65 65 0.65 1.01 (0.98-1.04)
4+ 21 0.48 13 0.68 0.71 (0.36-1.42)
ap=0.001; TWY=thousand woman-years.
Table IV Breast cancer by duration of OC ever-use. Standardised by the indirect method for age and parity at diagnosis, social class and
smoking habit at recruitment
All subjectSa Women ofparity Ib Women aged 30-34 Yearsc
Years Rate/TWY Ratios Rate/TWY Ratios Rate/TWY Ratio.s
of use (no.) (950% CI) (no.) (950% CI) (no.) (95% C!)
0 0.52 (96) 1.00 0.16 (7) 1.00 0.12 (4) 1.00
<2 (exc. 0) 0.54 (29) 1.04 (0.69-1.58) 0.43 (3) 2.69 (0.70-10.4) 0.36 (4) 3.00 (0.85-10.69)
2+3 0.83 (38) 1.60* (1.10-2.33) 1.49 (7) 9.31** (3.27-26.54) 0.40 (6) 3.33 (0.94-11.80)
4+5 0.77 (30) 1.48 (0.98-2.23) 1.43 (5) 8.94** (2.84-28.17) 0.49 (6) 4.08* (1.15-14.46)
6+7 0.42 (13) 0.80 (0.45-1.43) 1.56 (4) 9.75** (2.85-33.31) 0.26 (2) 2.17 (0.40-11.85)
8+9 0.44 (11) 0.85 (0.46-1.59) 0.65 (1) 4.06 (0.50-33.0) 0.30 (1) 2.50 (0.28-22.37)
10+ 0.75 (22) 1.44 (0.91-2.29) 0.00 (0) 1.22 (1) 10.17* (1.14-90.99)
*P<0.05; **P<0.01.
Tests for linear trends: aX2=0.867, P>0.05; b12 =4.351, P=0
TWY=Thousand women-years.
Table V Breast cancer by duration of OC current use
(women of parity 1). Standardised by the indirect method
for age at diagnosis, social class and smoking habit at
recruitment
Rate/TWY Ratios
Years of use (no.) (950% CI)
0 0.18 (7) 1.00
<2 (exc. 0) 0.42 (1) 2.33 (0.29-18.94)
2+ 3 1.02 (2) 5.67a (1.18-27.29)
4+ 5 1.27 (2) 7.06a (1.47-33.99)
6+7 0.84 (1) 4.67 (0.57-37.96)
8+9 1.23 (1) 6.83 (0.84-55.51)
10+ 0.00 (0)
Test for linear trend: X2=6.821, P=0.009; aP<0.05;
TWY=Thousand women-years.
years after stopping oral contraceptives. The trend is signifi-
cant (P=0.01). When the analysis is restricted to the appar-
ently vulnerable group of women aged 30 to 34 years when
their breast cancer was diagnosed, there is a steep increase
with the passage of years rising to a relative risk of 15.8
(P<0.05) in those women who had stopped OCs between 8
to 10 years previously. No further cases were reported after
a longer interval. Women who were parity 1 at the time of
).037; 'X2 =3.131, P>0.05; b.cStandardised for remaining variables;
diagnosis show a similar significantly increasing trend of risk
rising to a relative risk of 13.19 after ten years (P<0.0l).
These analyses provide some indication of a latent period
between exposure to OCs and the subsequent clinical presen-
tation of breast cancer.
We were unable to demonstrate any relationship between
breast cancer in users and the hormonal content of the OCs
they had ever-used.
There was a slightly higher proportion of breast cancer
cases of greater invasiveness (grade III) in those who had
used OCs (Table VII). In women under 35 years of age at
diagnosis, 48% of users were assessed as grade III compared
with 20% in the controls. However, the difference was not
statistically significant. There was no important difference in
the histological grades in older women. Material was unob-
tainable for 27% of ever-users and 32% of controls.
There is a possibility that OC users are screened more
frequently for breast cancer than non-users. When a subject
is reported as having breast cancer the women's general
practitioner is asked about the mode of presentation of the
lesion. This information was unavailable for 9% of cases and
8% of controls. Few of the breast lumps were discovered
during a screening procedure - 6% of those found in ever-
users and 4% in controls. This observation makes it unlikely
Table VI Breast cancer by recency of OC use. Standardised by the indirect method for age and parity at diagnosis, social class and smoking
habit at recruitment
All subjectsa Women ofparity Ib Women aged 30-34 years'
Years Rate/TWY Ratios Rate/TWY Ratios Rate/TWY Ratios
since use (no.) (950% CI) (no.) (95°/ CI) (no.) (95°/ CI)
Never used 0.52 (96) 1.00 0.16 (7) 1.00 0.12 (4) 1.00
<2 0.74 (22) 1.42 (0.89-2.26) 0.42 (2) 2.63 (0.55-12.66) 0.21 (3) 1.75 (0.39-7.82)
2+3 0.50 (14) 0.96 (0.55-1.68) 0.35 (1) 2.19 (0.27-17.80) 0.36 (3) 3.00 (0.67-13.40)
4+5 0.87 (22) 1.67* (1.05-2.65) 1.72 (4) 10.75** (3.15-36.72) 0.46 (2) 3.83 (0.70-20.91)
6+7 0.78 (15) 1.50 (0.87-2.58) 1.16 (2) 7.25* (1.51-34.90) 1.14 (2) 9.50* (1.74-51.87)
8+9 0.64 (9) 1.23 (0.62-2.44) 0.84 (1) 5.25 (0.65-42.67) 1.90 (1) 15.80* (1.77-141.37)
10+ 0.96 (17) 1.85* (1.10-3.10) 2.11 (3) 13.19** (3.41-51.01) 0.00 (0)
*P<0.05; **P<0.01.
Tests for linear trends: a2 =6.593, P=0.01; b2=27.226, P<0.0001; C2 =7.657, P=0.006; b'cStandardised for remaining vairiaibles;
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Table VII Histology of breast cancers
Aged <35 years Aged >35 years
Ever-users Controls Ever-users Controls
Grade No. % No. % No. % No. %
Intraduct 2 9.5 1 20.0 5 6.0 5 8.3
I 4 19.0 1 20.0 17 20.2 15 25.0
II 5 23.8 2 40.0 40 47.6 26 43.3
III 10 47.6 1 20.0 22 26.2 14 23.3
21 100.0 5 100.0 84 100.0 60 100.0
No information 7 1 31 30
TOTAL 28 6 115 90
that there was any material bias in the diagnosis of breast
cancer between users and controls.
The standardised mortality rate for the 41 ever-users who
died from breast cancer was 0.18 per thousand women-
years, and for the 29 controls it was 0.16, giving a mortality
relative risk of 1.17 (95% CI 0.73-1.88).
The survival times for women of all ages showed no
significant difference between users and controls. The five-
year survival rate of ever-users was 59.1% while that of
controls 63.9% (the number surviving and still under obser-
vation five years after diagnosis was 38 and 33, respectively).
When the analysis was restricted to women who were
diagnosed under the age of 35 years a significant difference
became apparent. The five-year survival of ever-users was
37.3% and that of the controls was 100% (P<0.01). How-
ever, only seven ever-users and three control subjects were
alive and still under observation five years after diagnosis.
Discussion
In our last publication (Royal College of General Practi-
tioners, 1981) we commented on the extraordinary instability
and diversity between the published results from various
other studies. Since that time some relevant issues have been
sharpened, but the essential incompatibilities between most
of the published reports have not been satisfactorily
explained. There is agreement that no overall effect of oral
contraceptives is demonstrable. However, some studies have
demonstrated adverse association in important subgroups,
essentially in younger women (Pike et al., 1981, 1983; Harris
et al., 1982; Olsson et al., 1985; Meirik et al., 1986).
McPherson and his colleagues (1987) have shown an
increased risk in users under 45 years of age at diagnosis
related to duration of OC use before the first term preg-
nancy, but the maximum risk became apparent only after a
latent period of 10 years from exposure had elapsed. Other
studies (Rosenberg et al., 1984; Cancer and Steroid Hor-
mone Study, 1986; Miller et al., 1986; Paul et al., 1986),
generally of at least equal power and merit, have failed to
demonstrate any adverse effects.
Our own data point towards some association between OC
use and a subsequently increased risk of breast cancer. Some
details of the associations demonstrated here are incompat-
ible with those in other studies with positive results, and
obviously totally contradict those studies which show no
association. No other study shows the same pattern of
associations evident in our data. Though clearly we have a
duty to interpret our own data as they present, it is crucial
to bear in mind the highly controversial and confusing
context of the other relevant research.
The increased risk in users under 35 years of age at
diagnosis is consistent with our 1981 report. In particular,
the relative risk in women diagnosed between 30 and 34
years of age remains significant at 3.33. Since our data are
cumulative this may not be surprising. However, those
women without breast cancer who were 30-34 years of age
at the time of our last analyses are now in the age group 35-
39 years where the incidence remains marginally below that
of the control subjects. It follows that this cohort of young
women has not carried a detectable increased risk of breast
cancer beyond 35 years of age when the natural incidence
begins rising sharply. McPherson and colleagues (1987) show
an increased risk extending to 45 years of age. In our data
the relative risk for women under 45 years old is 1.09 (95%
CI 0.77-1.55).
The observations in our analyses by parity (Table III)
suggest an interaction between oral contraceptive use and
birth order. By definition OC users who were nulliparous at
the time of the diagnosis of their breast cancer must all have
used OCs before their first term pregnancy. Nulliparous
women in general are a special group with an increased risk
of breast cancer compared with most parous women. The
group of users next most likely to have experienced substan-
tial use of OCs before their first full-term pregnancy is those
women who had had only one full-term pregnancy by the
time their breast cancer was diagnosed after their recruit-
ment to the study. Thus, the high risk demonstrated in
parity I cases is compatible with the hypothesis that it is use
of OCs before the first pregnancy that is the material time of
exposure.
The identification of users in parity 1 and those aged 30 to
34 years as groups at particular risk must be treated with
caution since- presumably by chance - the control rates in
these subgroups are unexpectedly low. It is probable that
there is a substantial proportion of subjects who have been
parity I at the ages of 30 to 34 years, so that the two low
rates are unlikely to have occurred independently. Control
rates at other ages were also lower than data reported
nationally. We attempted to apply an artificial correction to
the rate at 30 to 34 years by constructing a graph of age-
specific incidence rates in control subjects and eliminating
the dip at 30 to 34 years by interpolation. When this
adjusted rate was compared to that of ever-users the relative
risk remained raised to nearly 3.0, but it ceased to be
statistically significant.
Since the rate in ever-users in the parity 1 subgroup is
nearly six times greater than the control rate, the latter
would have to be dramatically higher before the differences
between the two rates ceased to be statistically significant.
The analyses of the time relationships in ever-users
provide supporting evidence for the identification of women
of parity 1 or aged 30 to 34 years as being particularly
associated with an increased risk of breast cancer. There is a
significant trend relating to duration of use for women of
parity 1 at the time of diagnosis in ever-users, and, surpris-
ingly, in current users. There is also a highly significant
trend relating to the passing of time in former users since
OCs were last used ('recency'). For women aged 30 to 34
years a time-trend is significant only in the recency analysis.
This suggests that an increased breast cancer risk is much
more strongly related to birth order than to age at
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If, as seems possible, the increased risk in parity 1 women
is an expression of the risk of use before the first full-time
pregnancy, it may be that the increased risk in younger
women is dependent upon the opportunity that particular
cohorts of women had of using OCs before their first term
pregnancy since they became widely popular in about 1965.
The delayed emergence of evidence of such an increased risk
is consistent with there being a latent interval of up to 20
years. Our analyses of recency suggest an increasing risk for
at least 10 years after stopping OCs and is consistent with a
latent period from exposure of 10 to 20 years.
If this hypothesis is correct we might expect that in years
to come the supposed increased risk of breast cancer in
former OC users would become increasingly apparent in
older women. Some aspects of our data suggest that the
prognosis may be less pessimistic.
An alternative interpretation of our analyses is that expo-
sure to oral contraceptives causes an acceleration of presen-
tation and development of breast cancer rather than an
initiation of malignant changes that would not otherwise
occur. In users under the age of 35 years there is a material
(though non-significant) increase in the histologically more
malignant grades, and this is associated with a significantly
poorer five year survival rate.
The natural history of breast cancer indicates that the
progression from cellular initiation to clinical presentation
takes many years, and possibly decades. Although we cannot
exclude a chance observation it is difficult to explain the
significantly increased risk in current users of parity 1 at
diagnosis after only two years of use, except as an accele-
ration to clinical presentation in women who had already
entered their pre-clinical phase when they started the pill.
For these women the latent period from exposure may be
short.
For women who are exposed at a very early stage of
cellular neoplasia, it would be reasonable to expect a latent
period of many years, and this would be consistent with the
rising incidence in young women in the years following the
cessation of pill use.
In our last publication based upon data available in 1980,
we demonstrated an increased risk in women aged 30 to 34
years. In fact, the effect had been evident in our data for
several years previously. Women who were aged 30 to 34
years at that time would not be contributing to the age
group 35 to 39 years. If they had carried an increased risk
with them we would expect this now to be apparent in this
older age group and it is not.
This supports the concept of an acceleration of clinical
presentation which becomes exhausted after 35 years of age.
An acceleration which produces an excess of cases under
the age of 35 years implies a deficit of cases in older women.
Those users who have contributed to the cumulative exper-
ience of age groups older than 45 would have had little
opportunity of substantial exposure to OC use before their
first term pregnancy and they are, therefore, irrelevant to the
present argument. In users aged 35 to 44 years there is a
small deficit of cases compared with the controls of 3 per
100,000 women annually, while there is an excess in women
under 35 years of 14 per 100,000 annually. Neither rate is
statistically significant.
We have been unable to demonstrate any association with
the progestogen dose in the combined pill, nor with the
oestrogen dose.
We believe that it is unlikely that our observations could
have arisen from any bias in the data. Approximately 95%
of both users and controls presented their breast cancer
spontaneously, so there is little likelihood of a diagnostic
bias. Breast self-examination has not generally been taught
by general practitioners throughout the long period that this
study has been conducted. Moreover, any tendency for this
activity to have been undertaken by OC users rather than
non-users should have been associated in users with a better
survival time whereas we have observed a poorer prognosis.
The substantial loss to follow-up was predominantly due to
change of address of study subjects, or the death or retire-
ment of their general practitioner. None of these circum-
stances is likely to be associated systematically with a change
of contraception, nor with morbidity. The characteristics of
the users who have been lost to follow-up are almost
identical to those of the controls who have similarly ceased
to remain under observation. All OC use was recorded
prospectively at the time of the prescription, so that the
possibility of a recall bias, which may be a problem in case-
control studies, does not arise in our data.
In conclusion, we have presented data which suggest that
OC use, probably before the first term birth, may be
associated with an increased rate of presentation of breast
cancer in women under the age of 35 years. In these women
the absolute excess risk is 14 cases per 100,000 annually
(95% CI: -0.1 to +35 per 100,000) or approximately one in
7,000 ever-users per year. It is possible on the basis of our
data that these excess cases in women under 35 years of age
are those that would have occurred later in these women if
they had not used OCs. There is no evidence of an
increased risk in women older than 35 years.
If these data were confirmed, it is possible that women
could accept the risks involved in exchange for the
undoubted benefits of oral contraceptives. Unfortunately, as
long as the substantial differences between the results of
studies remain unresolved, these interpretations must be
regarded as entirely conjectural. It is impossible at the
present time to determine whether or not the use of oral
contraceptives in the past is associated with any increased
risk of breast cancer.
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